Bone Biologics
BBLG
4 hedge funds and large institutions have $89.1K invested in Bone Biologics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
1,505% more capital invested
Capital invested by funds: $5.56K → $89.1K (+$83.6K)
100% more funds holding
Funds holding: 2 → 4 (+2)
0.75% more ownership
Funds ownership: 0.04% → 0.79% (+0.75%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$120K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.84K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.95K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $78.8K | +$120K | +6,167 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $9.05K | +$9.84K | +504 | +247% |
|
|
3
UBS Group
Zurich,
Switzerland
| $1.28K | +$1.95K | +100 | New |
|
4
Wells Fargo
San Francisco,
California
| $9 | – | – | – |
|
BBLG Hedge Fund Activity: Q1 2024 in Review
4 of the 6,944 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q1 2024, worth a combined $89.1K — up 1,505% from $5.56K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BBLG positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $120K.
- 4 institutional investors held Bone Biologics (BBLG) as of Q1 2024, up from 2 in Q4 2023.
- Funds reported $89.1K of Bone Biologics stock for Q1 2024, up 1,505% quarter-over-quarter.
- 2 funds opened new Bone Biologics positions in Q1 2024 and 0 closed out, a net change of +2 holders.
- The largest Bone Biologics buyer in Q1 2024 was Armistice Capital, an estimated $120K added.
Based on aggregated 13F filings for Q1 2024.